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Abstract Increased fucosylation of the type (sialyl) Lewisx was
detected on the acute-phase plasma protein K1-acid glycoprotein
(AGP) in patients with the congenital disorder of glycosylation
type IA. This is remarkable, because in these patients the
biosynthesis of guanosine 5P-diphosphate (GDP)-D-mannose is
strongly decreased, and GDP-D-mannose is the direct precursor
for GDP-L-fucose, the substrate for fucosyltransferases. The
concomitantly occurring increased branching of the glycans of
AGP and the increased fucosyltransferase activity in plasma
suggest that a chronic hepatic inflammatory reaction has induced
the increase in fucosylation. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Congenital disorder of glycosylation type IA (CDG-Ia) is a
genetic multisystem disorder, characterized by hypoglycosyla-
tion of N-linked glycans of glycoproteins due to phosphoman-
nomutase de¢ciency, a key enzyme in the biosynthesis of gua-
nosine 5P-diphosphate (GDP)-D-mannose (reviewed in [1]).
The decreased availability of GDP-D-mannose results in a
hypo-N-glycosylation of numerous plasma glycoproteins, e.g.
transferrin, K1-anti-trypsin, haptoglobin L-chain and K1-acid
glycoprotein (AGP) showing cathodical shifts upon electro-
phoresis. This is caused by the lack of one or more complete
N-linked glycans and the resulting reduction in the number of
sialic acid residues [1,2].
GDP-D-mannose is the precursor for the biosynthesis of
GDP-L-fucose [3^7], the L-fucose donor for fucosyltransfer-
ases. Therefore, an impairment of the fucosylation of glyco-
proteins is to be expected in CDG-Ia patients. Fucosylated
glycan structures play prominent roles, for example, in the
development of tissues and in the selectin-mediated leuko-
cyte^endothelial interactions. In this regard, especially K3-
linked fucose residues in the sialyl Lewisx con¢guration are
important as counter-receptors for selectins [8].
In this study we have investigated the fucosylation of var-
ious plasma acute-phase glycoproteins, and in particular
AGP, in patients with CDG-Ia. Crossed a⁄nity immunoelec-
trophoresis (CAIE) with concanavalin A (Con A) and Aleuria
aurantia lectin (AAL) was used to characterize the glycosyla-
tion of the plasma glycoproteins. High-pH anion-exchange
chromatography with pulsed amperometric detection
(HPAEC-PAD) of the PNGase-F released glycans was ap-
plied to con¢rm the CAIE ¢ndings for AGP. In addition,
the plasma K3-fucosyltransferase activity was measured as a
marker for the hepatic K3-fucosylation capacity [9].
2. Materials and methods
2.1. Materials
Con A Type V was obtained from Sigma (St. Louis, MO, USA)
and AAL and the AAL-HiTrap column from Biomed Labs (New-
castle-upon-Tyne, UK). The Carbopac PA-100 column was obtained
from Dionex (Sunnyvale, CA, USA) and the Mono-Q column and
1 ml desalting columns from Pharmacia (Uppsala, Sweden). Mono-
speci¢c goat anti-human AGP anti-serum was a kind gift of Dr. A.
Mackiewicz (Poznan, Poland). Rabbit anti-human K1-anti-chymotryp-
sin and anti-K1-protease inhibitor were purchased from Dakopatts
(Glostrup, Denmark). GDP-[14C]fucose, speci¢c radioactivity 5.15
Ci/ml, was obtained from NEN (Boston, MA, USA). All other ma-
terials used were of analytical grade and obtained from commercial
sources.
2.2. Sources of plasma
Eight typical CDG-Ia patients were studied; six of these patients
have been described [10,11]. Control blood plasma was taken from
healthy volunteers. Informed consent was obtained for all plasma
samples.
2.3. CAIE with Con A or AAL
In order to determine the reactivities of AGP, K1-anti-chymotrypsin
and K1-protease inhibitor with Con A and AAL, total plasma was
subjected to CAIE as described previously [12]. In short, 2 Wl of
plasma was subjected to electrophoresis in a polyacrylamide gel con-
taining Con A or AAL to fractionate the glycoproteins into a non-
retarded and various retarded glycoforms. The glycoforms were de-
tected by immunoelectrophoresis in a second dimension agarose gel
containing mono-speci¢c precipitating antibodies against one of the
glycoproteins and the precipitates were visualized as described [12].
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2.4. Characterization of AGP and its glycans
AGP was isolated from 0.5 ml of plasma [13]. SDS^PAGE of pu-
ri¢ed AGP, blotting on nitrocellulose and detection with anti-AGP
antibodies was performed as detailed elsewhere [12]. Treatment of 100
Wg of pure preparations of AGP with PNGase F and recovery of the
released glycans was performed as described earlier [13]. The lyophi-
lized glycans were dissolved in 200 Wl phosphate bu¡ered saline (PBS;
pH 8.6) and subjected to a⁄nity chromatography on a 5 ml AAL-
HiTrap column in PBS (1 ml/min). Non-retarded glycans (V0) were
collected in the void volume of the column and bound glycans were
eluted with 10 mM L-fucose in PBS (Vf). After desalting over a Bio-
Gel P2 column in milliQ water the Vf fraction was further subfractio-
nated according to charge by Mono-Q chromatography into Vf-1/2,
Vf-3 and Vf-4 (see scheme in Fig. 1). The Vf-1/2 fraction was dis-
carded because the amount of glycans was below detectable levels on
HPAEC-PAD. After desalting and lyophilization the Fractions V0,
Vf-3 and Vf-4 were dissolved in milliQ water and analyzed by
HPAEC-PAD using a Dionex PA-100 column (0.4U25 cm) [13].
The column was calibrated with non-fucosylated as well as K6- or
K3-fucosylated di-, tri- and tetrasialylated complex type oligosaccha-
rides that had been characterized by 1H-nuclear magnetic resonance.
2.5. Assay of K3-fucosyltransferase activity
The activity of plasma K3-fucosyltransferase in plasma was deter-
mined using calf fetuin as an acceptor [14]. All assays were performed
in duplicate for 16 h in 10 Wl of plasma.
3. Results
3.1. Molecular weight composition and lectin reactivity of AGP
At least two additional bands were detected for AGP of all
CDG-Ia patients on nitrocellulose blots of SDS^PAGE gels in
comparison to AGP obtained from controls (Fig. 2). The
bands showed a comparable cathodical shift to normal AGP
after desialylation (Fig. 2, lanes b). So, the lower molecular
weight bands do not represent undersialylation of the glycans,
but instead represent the lack of one or more glycans in ac-
cordance with the defect of CDG-Ia [1].
Analysis of the lectin reactivity of AGP with CAIE revealed
that the reactivity with Con A was decreased (Fig. 3) and with
AAL was increased in all patients (Fig. 4) in comparison to
normal AGP. The decrease in Con A reactivity was about the
same for all patients indicating a reduction of diantennary
complex type N-linked glycans on AGP [15]. In six out of
the eight patients studied a very strong increase in reactivity
with the fucose-speci¢c AAL was found (Fig. 4d); the two
other patients showed an intermediate and a low increase in
AAL reactivity (Fig. 4b,c). The increased AAL reactivities
indicate an elevated fucosylation of the glycans of AGP in
the CDG-Ia patients. Corresponding increases in AAL reac-
tivities were also found for two other acute-phase proteins,
K1-anti-chymotrypsin and K1-protease inhibitor I (results not
shown).
3.2. Characterization of the PNGase-F released glycans by
HPAEC-PAD
HPAEC-PAD analysis of the PNGase-F released glycans of
puri¢ed AGP was performed in order to investigate (a)
whether the strong increase in AAL reactivity indeed resulted
from an increase in fucosylation and (b) when so, whether K3-
or K6-linked fucose residues were responsible. HPAEC-PAD
Fig. 1. Scheme of the subfractionation of PNGase-F released
glycans from AGP prior to HPAEC-PAD analysis.
Fig. 2. Molecular weight compositions of native (a) and sialidase
treated (b) AGP of CDG-Ia patients and control AGP. AGP was
detected on nitrocellulose blots after SDS^PAGE of immunoprecipi-
tated AGP from patients P.A. (1), P.S. (2), dB.E. (3), R.M. (4) and
V.A. (5) as well as from control AGP. The same results were ob-
tained for J.I., A.V. and L.D.
Fig. 3. CAIE with Con A of AGP. a: Control plasma. b: Represen-
tative pattern for patients P.A. and P.S. c: Representative pattern
for dB.E., R.M., V.A., I.J., D.L. and V.A. CAIE was performed as
described in Section 2. The application site for the electrophoresis
of plasma samples in the ¢rst dimension gel was on the right-hand
side of each ¢gure; only the second dimension gels are shown. C0,
non-retarded AGP; Cw, weakly Con A-reactive AGP; Cs, strongly
Con A-reactive AGP. All AGP glycoforms were recovered at C0
when Con A was omitted from the ¢rst dimension gel.
FEBS 24781 9-4-01
W. Van Dijk et al./FEBS Letters 494 (2001) 232^235 233
analysis using the PA-100 column is well suited for these aims,
because fucosylated structures will elute earlier than the cor-
responding non-fucosylated structure. K6-Linked fucose on
the chitobiose core of N-linked glycans induces a shift of
31.8 min, whereas K3-linked fucose on a lactosaminyl unit
of a glycan will result in a cumulative shift of 35 to 36 min
per fucose residue present [16]. To prevent the occurrence of
overlapping peaks, the PNGase-F released glycans were sub-
fractionated according to the presence of fucose residues and
subsequently according to charge prior to analysis on
HPAEC-PAD (Fig. 1). The analyses were performed for
strongly AAL-reactive AGP obtained from the identical
twin sisters P.A. and P.S. (cf. Fig. 4d) and for low AAL-
reactive control AGP. In the case of the patients, the majority
of the free glycans bound strongly to the AAL-HiTrap col-
umn (fraction Vf), in accordance with their AAL reactivity in
CAIE, whereas for control AGP no more than 20% of the
glycans were recovered (not shown). The great majority of the
Vf fraction consisted of fucosylated tri- and tetrasialylated
glycans (Vf-3, respectively, Vf-4), in view of the fact that
mono- and disialylated glycans were undetectable after
Mono-Q chromatography in this fraction. The HPAEC-
PAD pro¢les obtained for V0, Vf-3 and Vf-4 of P.A. (Fig.
5, left) were identical to those of her twin sister P.S. (not
shown), but di¡ered markedly from control (Fig. 5, right).
CDG-Ia AGP appeared to have a higher content of tri- and
tetraantennary glycans with two or three fucose residues than
the control. This is concluded from the much lower recovery
of materials at elution positions of standard non-fucosylated
tri- and tetrasialylated glycans in V0 than in control AGP,
and the increased recovery at positions of standard di- and
trifucosylated glycans in Vf-3 and Vf-4 in the case of CDG-Ia
AGP. Apparently, the glycans present in Vf-3 and Vf-4 did
not contain K6-linked fucose, but only K3-linked residues,
because of the absence of eluted materials close to (i.e. at
31.8 min) the positions of the corresponding non-fucosylated
standards. Finally, it can be deduced from the various
HPAEC-PAD pro¢les that in the patients the content of dian-
tennary glycans of AGP was lower than in control AGP in
agreement with the decreased reactivity with Con A in CAIE
(cf. Fig. 3).
3.3. Activity of plasma K3-fucosyltransferase
The plasma K3-fucosyltransferase activity was higher
(4.1 þ 0.4 pmol/min/ml) in the ¢ve patients with strongly
AAL-reactive AGP, than in control plasma (2.5 þ 0.9 pmol/
min/ml). The enzyme activity was normal (1.9 pmol/min/ml)
in the plasma of patient dB.E. were the AAL reactivity of
AGP was only slightly higher than in control plasma (see
Fig. 4b).
4. Discussion
The results of this study clearly show that in patients with
CDG-Ia the fucosylation of AGP is increased, albeit to di¡er-
ent extents. This is a remarkable ¢nding because GDP-L-fu-
cose is the donor for the fucosylation reaction, but the avail-
ability of GDP-D-mannose, its major biosynthetic precursor,
is decreased in CDG-Ia patients [1,2]. The increase in fucosy-
lation was not restricted to AGP, since it was also found for
two other plasma acute-phase proteins synthesized by the liv-
er, K1-anti-chymotrypsin and K1-protease inhibitor. The
HPAEC-PAD analyses (Fig. 5) demonstrated that the in-
crease in fucosylation of AGP involved a substitution of the
lactosaminyl branches of tri- and tetrasialylated glycans with
L-fucose in an K3-linkage, also known as the Lewisx blood
group determinant. This results in an increase in mono- as
Fig. 4. CAIE with AAL of AGP. a: Control plasma. b: Patient
dB.E. c: Patient R.M. d: Representative pattern for patients P.A.,
P.S., L.S., V.A., I.J., D.L. and S.L. A0, non-retarded AGP; Aw,
weakly AAL-reactive AGP; As, strongly AAL-reactive AGP. All
AGP glycoforms were recovered at A0 when AAL was omitted
from the ¢rst dimension gel. See legend of Fig. 3 for further details.
Fig. 5. HPAEC-PAD analysis of PNGase-F released glycans. The
PNGase-F released glycans were subfractionated according to the
scheme in Fig. 1 and subjected to HPAEC-PAD analysis on the
PA-100 column. V0, non-retarded fraction on AAL-HiTrap column;
Vf-3 and Vf-4, tri-, respectively, tetrasialylated AAL-HiTrap binding
fraction as obtained by Mono-Q anion-exchange chromatography.
Left panel: Patient P.A; right panel: control. 2S, 3S and 4S repre-
sent elution positions of standard di-, tri-, respectively, tetrasialy-
lated complex type oligosaccharides; 0F, 1F, 2F, 3F and 4F repre-
sent standard non-, mono-, di-, tri-, respectively, tetra-K3-
fucosylated complex type trisialylated (middle panels) or tetrasialy-
lated (lower panels) oligosaccharides.
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well as di- and trifucosylated tri- and tetrasialylated glycans,
and consequently in an increase in sialyl Lewisx determinants
on AGP.
An increased expression of sialyl Lewisx determinants on
AGP has been shown to indicate the occurrence of a hepatic
in£ammatory response [12,17], which is of a chronic type
when the extent of branching of the glycans of AGP is also
increased [17]. Remarkably, this study shows that correspond-
ing type of changes in glycosylation of AGP occur in the
CDG-Ia patients. This suggests that the strong increase in
fucosylation observed in the majority of the CDG-Ia patients
is induced by a chronic hepatic in£ammatory response. The
occurrence of such a response is also indicated by the elevated
activity of plasma K3-fucosyltransferase, a marker for in-
creased hepatic fucosylation, which generally coincides with
acute and chronic hepatic in£ammatory responses [9,17]. Con-
sequently, these patients seem to occur in a continuous state
of in£ammation. Normally, this will result also in a decrease
in the plasma concentration of albumin. Indeed, hypoalbumin-
aemia is observed in these patients, which as yet was not
totally explainable by circulatory losses associated with, for
example, nephritic syndrome or diarrhea in these patients [1].
It is tempting to speculate that the high expression of sialyl
Lewisx groups on AGP is helpful in the defense against com-
plications of CDG. Such decorated AGP molecules have been
shown to be able to interact with E-selectin and thus might
counteract excessive selectin-mediated attraction of leukocytes
into in£amed tissues [17,18].
It can be considered that the CDG-induced increase in the
extent of branching of the glycans in itself will have induced
an increase in K3-fucosylation, because the tri- and tetraan-
tennary glycans on AGP can be regarded to be better accep-
tors for K3-fucosyltransferase than di-antennary glycans.
However, in two out of eight patients, only a low or moderate
increase in fucosylation of AGP was observed (see Fig. 4b,c),
despite the fact that these patients (dB.E. and R.M.) belonged
to the group with a high content of tri- and tetraantennary
glycans according to CAIE with Con A (cf. relative content of
C0 in Fig. 3a^c).
Finally, we cannot exclude that in CDG-Ia patients an in-
creased availability of GDP-L-fucose has contributed to the
increased fucosylation. Two biosynthetic pathways for GDP-
L-fucose are known: (i) the more common route starting from
GDP-D-mannose and (ii) a slowly occurring direct formation
from L-fucose-1-phosphate [3^7]. It is not known whether the
latter route is normally suppressed, e.g. by feed-back inhibi-
tion of GDP-L-fucose formed via the GDP-D-mannose route
or by inhibition through GDP-Man. But if so, this cannot
occur in the liver of CDG-Ia patients and consequently will
result in a higher production along this route. Alternatively,
the low availability of GDP-D-mannose may have changed the
kinetics of the GDP-D-mannose-dependent route in an unex-
pected direction, i.e. a higher production of GDP-L-fucose, as
has been detected in homogenates of Perinereis cultrifera oo-
cytes [5]. Studies are in progress to delineate the synthesis
route of GDP-fucose in ¢broblasts of CDG-Ia patients.
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